Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fevipiprant + montelukast
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Fevipiprant (QAW039)** is a potent, selective antagonist of the prostaglandin D2 receptor 2 (DP2/CRTh2) developed for the treatment of moderate to severe asthma, particularly in patients with eosinophilic inflammation. **Montelukast** is a leukotriene receptor antagonist used for the chronic prophylaxis and treatment of asthma and to relieve symptoms of allergic rhinitis. The combination **fevipiprant + montelukast** is not an approved commercial product but has been investigated in clinical trials to test the additive or synergistic effects on asthma control, with both drugs targeting distinct inflammatory pathways implicated in asthma pathophysiology[1][2][3][4].
- Other names
- fevipiprant + montelukastQAW039 + montelukast
02
Targets
Sucrase-IsomaltaseALOX12 (Arachidonate 12-lipoxygenase, 12S type)UreaseCYSLTR1 (Cysteinyl-leukotriene type 1 receptor)ALPL (Tissue-nonspecific alkaline phosphatase)PTGDR2 (Prostaglandin D2 receptor 2)
Beyond the preview
Go deeper on fevipiprant + montelukast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fevipiprant + montelukast.